Accord Healthcare launches Herceptin (trastuzumab) biosimilar (Zercepac) in UK

The European Commission approval of Zercepac was based on a number of clinical studies including comparative quality studies, preclinical and clinical studies, confirming biosimilarity and comparable efficacy and safety to Herceptin.

Source:

PharmaTimes